{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,6]],"date-time":"2026-10-06T14:07:21Z","timestamp":1791295641884,"version":"4.1.0"},"reference-count":24,"publisher":"Elsevier BV","issue":"3","license":[{"start":{"date-parts":[[2015,3,1]],"date-time":"2015-03-01T00:00:00Z","timestamp":1425168000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2015,3,1]],"date-time":"2015-03-01T00:00:00Z","timestamp":1425168000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["American Heart Journal"],"published-print":{"date-parts":[[2015,3]]},"DOI":"10.1016\/j.ahj.2014.12.012","type":"journal-article","created":{"date-parts":[[2015,1,6]],"date-time":"2015-01-06T20:03:23Z","timestamp":1420574603000},"page":"404-411.e3","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":32,"title":["Galectin-3 and mineralocorticoid receptor antagonist use in patients with chronic heart failure due to left ventricular systolic dysfunction"],"prefix":"10.1016","volume":"169","clinical-trial-number":[{"clinical-trial-number":"nct00351390","registry":"10.18810\/clinical-trials-gov"}],"author":[{"given":"Parul U.","family":"Gandhi","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shweta R.","family":"Motiwala","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Arianna M.","family":"Belcher","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hanna K.","family":"Gaggin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rory B.","family":"Weiner","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Aaron L.","family":"Baggish","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mona","family":"Fiuzat","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hans-Peter","family":"Brunner-La Rocca","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"suffix":"Jr.","given":"James L.","family":"Januzzi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.ahj.2014.12.012_bb0005","doi-asserted-by":"crossref","first-page":"433","DOI":"10.1161\/ATVBAHA.107.159160","article-title":"Galectin-3 is an amplifier of inflammation in atherosclerotic plaque progression through macrophage activation and monocyte chemoattraction","volume":"28","author":"Papaspyridonos","year":"2008","journal-title":"Arterioscler Thromb Vasc Biol"},{"key":"10.1016\/j.ahj.2014.12.012_bb0010","doi-asserted-by":"crossref","first-page":"3121","DOI":"10.1161\/01.CIR.0000147181.65298.4D","article-title":"Galectin-3 marks activated macrophages in failure-prone hypertrophied hearts and contributes to cardiac dysfunction","volume":"110","author":"Sharma","year":"2004","journal-title":"Circulation"},{"key":"10.1016\/j.ahj.2014.12.012_bb0015","doi-asserted-by":"crossref","first-page":"1217","DOI":"10.1016\/j.jacc.2006.03.061","article-title":"Utility of amino-terminal pro-brain natriuretic peptide, galectin-3, and apelin for the evaluation of patients with acute heart failure","volume":"48","author":"van Kimmenade","year":"2006","journal-title":"J Am Coll Cardiol"},{"key":"10.1016\/j.ahj.2014.12.012_bb0020","doi-asserted-by":"crossref","first-page":"60","DOI":"10.3109\/07853890.2010.538080","article-title":"Predictive value of plasma galectin-3 levels in heart failure with reduced and preserved ejection fraction","volume":"43","author":"de Boer","year":"2011","journal-title":"Ann Med"},{"key":"10.1016\/j.ahj.2014.12.012_bb0025","doi-asserted-by":"crossref","first-page":"72","DOI":"10.1161\/CIRCHEARTFAILURE.111.963637","article-title":"Galectin-3 in ambulatory patients with heart failure: results from the HF-ACTION study","volume":"5","author":"Felker","year":"2012","journal-title":"Circ Heart Fail"},{"key":"10.1016\/j.ahj.2014.12.012_bb0030","doi-asserted-by":"crossref","first-page":"1157","DOI":"10.1093\/eurjhf\/hft075","article-title":"Serial measurement of galectin-3 in patients with chronic heart failure: results from the ProBNP Outpatient Tailored Chronic Heart Failure Therapy (PROTECT) study","volume":"15","author":"Motiwala","year":"2013","journal-title":"Eur J Heart Fail"},{"key":"10.1016\/j.ahj.2014.12.012_bb0035","doi-asserted-by":"crossref","first-page":"67","DOI":"10.1161\/ATVBAHA.112.300569","article-title":"Galectin-3 mediates aldosterone-induced vascular fibrosis","volume":"33","author":"Calvier","year":"2013","journal-title":"Arterioscler Thromb Vasc Biol"},{"key":"10.1016\/j.ahj.2014.12.012_bb0040","doi-asserted-by":"crossref","first-page":"237","DOI":"10.1007\/s10557-014-6520-2","article-title":"Galectin-3: a modifiable risk factor in heart failure","volume":"28","author":"de Boer","year":"2014","journal-title":"Cardiovasc Drugs Ther"},{"key":"10.1016\/j.ahj.2014.12.012_bb0045","article-title":"Galectin-3 and heart failure: prognosis, prediction, & clinical utility","author":"Filipe","year":"2014","journal-title":"Clin Chim Acta"},{"key":"10.1016\/j.ahj.2014.12.012_bb0050","first-page":"e240","article-title":"2013 ACCF\/AHA Guideline for the Management of Heart Failure: a report of the American College of Cardiology Foundation\/American Heart Association Task Force on Practice Guidelines","volume":"128","author":"Yancy","year":"2013","journal-title":"Circulation"},{"key":"10.1016\/j.ahj.2014.12.012_bb0055","doi-asserted-by":"crossref","first-page":"1881","DOI":"10.1016\/j.jacc.2011.03.072","article-title":"Use of amino-terminal pro-B-type natriuretic peptide to guide outpatient therapy of patients with chronic left ventricular systolic dysfunction","volume":"58","author":"Januzzi","year":"2011","journal-title":"J Am Coll Cardiol"},{"key":"10.1016\/j.ahj.2014.12.012_bb0060","doi-asserted-by":"crossref","first-page":"532","DOI":"10.1016\/j.ahj.2010.01.005","article-title":"Design and methods of the Pro-B Type Natriuretic Peptide Outpatient Tailored Chronic Heart Failure Therapy (PROTECT) study","volume":"159","author":"Bhardwaj","year":"2010","journal-title":"Am Heart J"},{"key":"10.1016\/j.ahj.2014.12.012_bb0065","doi-asserted-by":"crossref","first-page":"385","DOI":"10.1016\/j.amjcard.2011.03.056","article-title":"Usefulness of plasma galectin-3 levels in systolic heart failure to predict renal insufficiency and survival","volume":"108","author":"Tang","year":"2011","journal-title":"Am J Cardiol"},{"key":"10.1016\/j.ahj.2014.12.012_bb0070","doi-asserted-by":"crossref","first-page":"197","DOI":"10.3909\/ricm0726","article-title":"Utilization of galectin-3 in case management across the spectrum of heart failure","volume":"15","author":"McCullough","year":"2014","journal-title":"Rev Cardiovasc Med"},{"key":"10.1016\/j.ahj.2014.12.012_bb0075","doi-asserted-by":"crossref","first-page":"221","DOI":"10.2217\/fca.14.9","article-title":"Using galectin-3 to reduce heart failure rehospitalization","volume":"10","author":"Xue","year":"2014","journal-title":"Future Cardiol"},{"key":"10.1016\/j.ahj.2014.12.012_bb0080","doi-asserted-by":"crossref","first-page":"38","DOI":"10.1016\/j.cardfail.2013.11.011","article-title":"Relationship between galectin-3 levels and mineralocorticoid receptor antagonist use in heart failure: analysis from HF-ACTION","volume":"20","author":"Fiuzat","year":"2014","journal-title":"J Card Fail"},{"key":"10.1016\/j.ahj.2014.12.012_bb0085","doi-asserted-by":"crossref","first-page":"11","DOI":"10.1056\/NEJMoa1009492","article-title":"Eplerenone in patients with systolic heart failure and mild symptoms","volume":"364","author":"Zannad","year":"2011","journal-title":"N Engl J Med"},{"key":"10.1016\/j.ahj.2014.12.012_bb0090","doi-asserted-by":"crossref","first-page":"1206","DOI":"10.1161\/CIRCHEARTFAILURE.113.000457","article-title":"Soluble concentrations of the interleukin receptor family member ST2 and beta-blocker therapy in chronic heart failure","volume":"6","author":"Gaggin","year":"2013","journal-title":"Circ Heart Fail"},{"key":"10.1016\/j.ahj.2014.12.012_bb0095","doi-asserted-by":"crossref","first-page":"1088","DOI":"10.1016\/j.ahj.2009.04.001","article-title":"Left ventricular remodeling after acute myocardial infarction: does eplerenone have an effect?","volume":"157","author":"Weir","year":"2009","journal-title":"Am Heart J"},{"key":"10.1016\/j.ahj.2014.12.012_bb0100","doi-asserted-by":"crossref","first-page":"737","DOI":"10.1016\/j.amjcard.2014.05.062","article-title":"Effect of spironolactone on 30-day death and heart failure rehospitalization (from the COACH Study)","volume":"114","author":"Maisel","year":"2014","journal-title":"Am J Cardiol"},{"key":"10.1016\/j.ahj.2014.12.012_bb0105","doi-asserted-by":"crossref","first-page":"65","DOI":"10.1016\/j.jchf.2013.10.005","article-title":"Head-to-head comparison of serial soluble ST2, growth differentiation factor-15, and highly-sensitive troponin t measurements in patients with chronic heart failure","volume":"2","author":"Gaggin","year":"2014","journal-title":"JACC Heart Fail"},{"key":"10.1016\/j.ahj.2014.12.012_fr0010","doi-asserted-by":"crossref","first-page":"1440","DOI":"10.1016\/j.echo.2005.10.005","volume":"18","author":"Lang","year":"2005","journal-title":"J Am Soc Echocardiogr"},{"key":"10.1016\/j.ahj.2014.12.012_fr0015","doi-asserted-by":"crossref","first-page":"20","DOI":"10.1056\/NEJMoa1114248","article-title":"Estimating glomerular filtration rate from serum creatinine and cystatin C","volume":"367","author":"Inker","year":"2012","journal-title":"N Engl J Med"},{"key":"10.1016\/j.ahj.2014.12.012_fr0020","first-page":"198","article-title":"Patients self-assessment of their congestive heart failure: content, reliability and validity of a new measure, the Minnesota Living with Heart Failure Questionnaire","volume":"3","author":"Rector","year":"1987","journal-title":"Heart Fail"}],"container-title":["American Heart Journal"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0002870315000022?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0002870315000022?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,11,2]],"date-time":"2025-11-02T09:55:52Z","timestamp":1762077352000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0002870315000022"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2015,3]]},"references-count":24,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2015,3]]}},"alternative-id":["S0002870315000022"],"URL":"https:\/\/doi.org\/10.1016\/j.ahj.2014.12.012","relation":{},"ISSN":["0002-8703"],"issn-type":[{"value":"0002-8703","type":"print"}],"subject":[],"published":{"date-parts":[[2015,3]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Galectin-3 and mineralocorticoid receptor antagonist use in patients with chronic heart failure due to left ventricular systolic dysfunction","name":"articletitle","label":"Article Title"},{"value":"American Heart Journal","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.ahj.2014.12.012","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"Copyright \u00a9 2015 Elsevier Inc. All rights reserved.","name":"copyright","label":"Copyright"}]}}